TWD
RNA

True Wealth Design’s Atrium Therapeutics RNA Stock Holding History

True Wealth Design’s Portfolio RNA Stock Details RNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.87K Buy
213
+212
+21,200% +$2.77K ﹤0.01% 1553
2026
Q1 		$14 Buy
+1
New +$14 ﹤0.01% 2659

Other funds holding RNA

TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.12B AUM 34.21% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
TM
Torren Management San Diego, California $197M AUM

True Wealth Design's RNA Position: Q2 2026 in Review

True Wealth Design increased its Atrium Therapeutics (RNA) stake by 21,200% in Q2 2026, buying an estimated $2.77K and bringing the position to 213 shares worth $2.87K. The position accounts for ﹤0.01% of the portfolio, ranked #1553.

True Wealth Design first reported a position in RNA in Q1 2026 and has held it in 2 quarters since. 8 funds tracked by Wall St. Rank hold RNA as of Q2 2026.

  • True Wealth Design held 213 shares of Atrium Therapeutics worth $2.87K as of Q2 2026.
  • True Wealth Design bought 212 Atrium Therapeutics shares in Q2 2026, an estimated $2.77K.
  • Atrium Therapeutics made up ﹤0.01% of True Wealth Design's portfolio in Q2 2026, its #1553 holding.
  • True Wealth Design first reported a position in Atrium Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 8 funds tracked by Wall St. Rank held Atrium Therapeutics as of Q2 2026.

Based on True Wealth Design's 13F filing for Q2 2026, filed 16 Jul 2026.